IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

DOJ Sues KV Pharmaceutical Over Adulterated Drug Production

11:27 PM MDT | March 22, 2009 | DEEPTI RAMESH

The U.S. Department of Justice (DOJ) has filed a lawsuit to block KV Pharmaceutical (St. Louis), its subsidiaries Ethex and Ther-Rx, as well as its principal officers from manufacturing and distributing adulterated and unapproved drugs. KV has agreed to the injunction in a consent decree, DOJ says. KV Pharmaceutical is a specialty drugmaker that develops, manufactures, and markets branded and generic prescription products and had revenues of about $600 million in fiscal 2008. FDA says it conducted inspections of the company’s facilities between December...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa